[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 9, 1997

Perspectives on Hepatitis B Vaccination-Reply

Author Affiliations

Merck & Co Inc Whitehouse Station, NJ

JAMA. 1997;277(14):1124. doi:10.1001/jama.1997.03540380038025

In Reply.  —The Landmark Perspective article was written in response to a request from the editors of JAMA to provide a historical perspective on the Landmark Article by Buynak et al.1 The purpose of the Perspective was to trace the development of hepatitis B vaccines and to show how they can be used to eliminate and eventually eradicate hepatitis B infection, and with it many cases of cirrhosis and cancer of the liver, from the human population. My article was not intended to provide complete information about hepatitis B vaccines.Dr Waisbren must know that lawsuits and isolated case reports of adverse events occurring in temporal association with vaccination do not prove a causal relationship. In fact, the Vaccine Safety Committee of the Institute of Medicine examined 4 types of evidence to determine if a causal Association exists between the administration of certain types of vaccines and selected adverse experiences. They